Investors May Lead Securities Fraud Lawsuit Against MoonLake Immunotherapeutics

Investors May Lead Class Action Lawsuit Against MoonLake Immunotherapeutics

The Rosen Law Firm, a prominent global legal entity focused on investor rights, has issued a critical reminder for those who have purchased common stock in MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024, and September 29, 2025. The firm has highlighted a pivotal date: December 15, 2025, which is the deadline for investors interested in becoming lead plaintiffs in a forthcoming class action lawsuit.

If you acquired shares of MoonLake during the specified timeframe, you may be eligible for compensation without incurring any upfront fees or costs—an arrangement facilitated through a contingency fee structure. This means that legal fees will only be paid if the action results in financial recovery for investors.

What Investors Should Do Next

Participation in the MoonLake class action is straightforward. Interested investors are encouraged to visit Rosen Law Firm's webpage or to reach out directly to Phillip Kim, Esq. at the firm. He can be contacted toll-free at 866-767-3653 or via email at [email protected]. If you choose to be a lead plaintiff, it is vital to file your motion with the court by the December 15 deadline. The lead plaintiff serves as a representative for other members of the class in steering the litigation.

The Rosen Law Firm's Legal Background

The Rosen Law Firm recommends that investors seek legal representation with proven experience in securities class action lawsuits. Notably, many firms claiming to represent investors often lack substantial courtroom experience in these cases. In contrast, the Rosen Law Firm has earned a reputation for successful outcomes, such as obtaining the largest-ever securities class action settlement involving a Chinese company. The firm ranked No. 1 by ISS Securities Class Action Services for the number of settlements achieved in 2017 and has continually placed among the top four since 2013, collectively recovering hundreds of millions of dollars on behalf of investors. In just 2019, they secured over $438 million, with founding partner Laurence Rosen being recognized as a Titan of the Plaintiffs' Bar by Law360.

Details of the Case Against MoonLake Immunotherapeutics

The class action lawsuit is founded on claims that throughout the specified period, the defendants made misleading statements about their products, particularly regarding the efficacy of their Nanobodies in comparison to traditional monoclonal antibodies. The lawsuit alleges that revelations about the true nature of these products led to investor losses, as the market did not have an accurate understanding of the clinical capabilities and advantages purportedly offered by MoonLake’s offerings.

Investors are urged to stay updated through their social media channels, including LinkedIn, Twitter, and Facebook. It is important to note that until a class is officially certified, potential claimants are not represented by counsel unless they select an attorney of their own. Investors can also decide to remain as absent class members and take no further action if they prefer.

In conclusion, as the deadline approaches, investors in MoonLake Immunotherapeutics have a unique opportunity to participate in a significant class action lawsuit. Those who took part in the stock purchases during the defined period should consider their options carefully and may want to consult with legal counsel to explore their rights and potential claims.